Heterocyclic compounds as PI3kα inhibitors
Heterocyclic compounds selectively inhibit PI3Ka to overcome the limitations of current PI3K inhibitors, enhancing tumor treatment efficacy while minimizing side effects.
WO2026128684A1PCT designated stage Publication Date: 2026-06-18PIKAVATION THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- PIKAVATION THERAPEUTICS INC
- Filing Date
- 2025-12-11
- Publication Date
- 2026-06-18
AI Technical Summary
⚠Technical Problem
Current PI3K inhibitors face challenges in achieving sufficient target inhibition in tumors while avoiding toxicity in cancer patients due to their lack of isoform selectivity, leading to side effects such as hyperglycemia and rash, diarrhea, myelosuppression, and transaminitis.
⚗Method used
Development of heterocyclic compounds that selectively inhibit PI3Ka, reducing the risk of toxicity by targeting mutant PI3Ka without affecting wild-type PI3Ka, thereby minimizing side effects like hyperglycemia and hyperinsulinemia.
🎯Benefits of technology
The heterocyclic compounds provide enhanced selectivity for mutant PI3Ka, increasing the therapeutic window and allowing effective tumor inhibition with reduced adverse effects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025059156_18062026_PF_FP_ABST
Abstract
The present application provides heterocyclic compounds of formula I that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.
Need to check novelty before this filing date? Find Prior Art